Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. - Wikidata - awgldk - TriplyDB

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

http://www.wikidata.org/entity/Q37064758

about

Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28 Editors' pick 2013.Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model.Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Anti-CD28 Antibody-Initiated Cytokine Storm in Canines.Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm Costimulation Blockade in Kidney Transplantation: An Update Novel antibodies targeting immune regulatory checkpoints for cancer therapy.Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.Biological therapies: a long way on from Jenner

P2860

Q28081577-AD7684C4-3E09-4E53-901B-C9A3BAA817EB Q33573593-F665A8C7-7EA1-4791-93BC-BAA2E574258A Q33582058-7646705A-94A8-430B-A713-3DD82C3A8036 Q34803897-405EB306-08C3-49EF-B60A-813998A24006 Q35152029-1C714310-046F-4AA5-9F2A-2A8D52AED62B Q35610659-B3984971-F27C-486B-BC76-4CE18FE99047 Q36113141-5E7AFEC6-07D6-4CCC-8B8B-9A2C96B7C099 Q36214559-1B7B1393-DD00-44BF-BECD-17945F2368FF Q36621100-B901A64A-3E47-4BE5-A76E-AA158D585DAF Q37375148-6D563E7B-2949-45CC-B3B7-CB18B81AC8A4 Q38108836-3034ECB2-4BA6-43C8-B40E-A593B235D3BF Q40617738-F31C1BAB-9176-4C8B-9CF6-6C71C46B7421 Q41883888-1595A768-0B99-4924-946D-E3990FC6485F

P2860

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

http://www.wikidata.org/entity/Q37064758

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

@en

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

@nl

type

label

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

@en

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

@nl

prefLabel

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

@en

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

@nl

P1433

Q37064758-8C5C8A42-3DCE-4B0A-8696-B6F45A1F404B

P1476

Q37064758-CAD68D77-74FC-4D47-B7F8-50DC7E2FC443

P2093

Q37064758-040588FE-BBFC-488A-BF19-F42FFEFD9BFE

Q37064758-078571ED-4732-44D4-BE29-CC6A960F0663

Q37064758-0BBAE266-7FDA-48C7-B251-4CA448DA9DF9

Q37064758-64B80259-20E6-4647-9F46-40D8B2197CA1

Q37064758-9162EF6E-DBC9-471A-842B-4406FE080FBA

Q37064758-AAC53322-06BA-426C-B7AD-8125512D61BA

Q37064758-C489FEEB-1F1C-4C7E-8093-75657F6813DA

Q37064758-E6294F22-921F-4F52-ACFD-3839386B13E7

Q37064758-ECBB0E24-8A41-4C7C-AFD4-124E35107B5A

P2860

Q37064758-0EE5394D-E4F7-4168-B30E-AA5E477D7E4D

Q37064758-153ABAAF-7104-47DA-8457-7D80A4E66D94

Q37064758-2147DC80-4CA7-43B6-B824-7C2E68FC4133

Q37064758-2ACD8287-4E27-4CCD-9401-B7199FA0010C

Q37064758-5C499937-CB0F-4F26-8255-F44296A78A59

Q37064758-5CC3283A-1293-4E50-BB58-F6634272E468

Q37064758-5CD499B9-4E0D-48ED-9F71-90C38CCE6BF6

Q37064758-65DE3F1E-8730-44FE-9B5C-E74BBE8A7A26

Q37064758-6F31D426-CA1C-4B80-BA69-FDC55E2A99A1

Q37064758-749CDDD3-14D7-4923-985B-E2E8BF39B7AC

P304

Q37064758-0CBDC89E-85BA-4B7E-BE5A-47CC52B8A50B

P31

Q37064758-D3C99E79-AF33-4642-B083-0060A63606F1

P356

Q37064758-E5EAFAC9-CEB1-45DA-81E8-20A5B28CDA98

P407

Q37064758-534839C2-5514-4AAA-8408-DE170389E484

P433

Q37064758-305B8C73-B246-4825-9C7F-080DF21A6B6C

P478

Q37064758-0587308E-9D38-46A8-AB56-D757950006F0

P50

Q37064758-1913EF6F-8D05-4182-B6F3-071B4433AE73

P577

Q37064758-CDC5B140-DC7F-4AE2-A3DB-9EF74DF3BA7D

P5875

Q37064758-F184A801-B6FE-49D6-9DFA-BA80695FD3C2

P698

Q37064758-D8204122-BB60-4362-AB0B-D03C2D2D3B0C

P921

Q37064758-B7D3BF0C-558A-41D1-B890-6F5B288B9B1B

P932

Q37064758-80420959-50F1-415C-BE4D-36A45D4AF196

P356

P1433

British Journal of Clinical Pharmacology

P1476

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release

@en

P2093

Chris Bird

http://www.w3.org/2001/XMLSchema#string

David Eastwood

http://www.w3.org/2001/XMLSchema#string

Jason Hockley

http://www.w3.org/2001/XMLSchema#string

Lucy Findlay

http://www.w3.org/2001/XMLSchema#string

Meenu Wadhwa

http://www.w3.org/2001/XMLSchema#string

Paula Dilger

http://www.w3.org/2001/XMLSchema#string

Robin Thorpe

http://www.w3.org/2001/XMLSchema#string

Stephen Poole

http://www.w3.org/2001/XMLSchema#string

Susan J Thorpe

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotoxicity of monoclonal antibodies

A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells

Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.

IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508.

Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF-alpha, and IL-1 beta.

Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies.

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.

P304

299-315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12165

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236906226

http://www.w3.org/2001/XMLSchema#string

P698

23701319

http://www.w3.org/2001/XMLSchema#string

P921

P932

3731604

http://www.w3.org/2001/XMLSchema#string